On Oct. 16, President Trump promised to slash the price of brand-name GLP-1 drugs like Ozempic and Wegovy to $150 a month. Even after a top health official suggested price negotiations between drugmakers and the administration were ongoing, the announcement sent Novo Nordisk and Eli Lilly stocks tumbling. For patients who’ve been priced out, that number sounded like relief.
I got three texts within an hour: “Does this mean we won’t need the research suppliers anymore?” “Can we go back to real pharmacies?” “Dr. Dothée, is this real?” That’s what my friends call me.
